Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigation of pharmacologic interactions between omeprazole and tacrolimus in a membranous nephropathy patient with CYP3A5 nonexpresser: a case report.

Pharmacogenetics and genomics - 1 Sept 2022

Li Yanli, Liu Yi, Sun Zengxian

Abstract excerpt

Tacrolimus has been widely used in membranous nephropathy in recent years. The drug interactions of the coadministration of tacrolimus with omeprazole in CYP3A5 nonexpresser membranous nephropathy patients have not been demonstrated. Here, we report an idiopathic membranous nephropathy patient who was with CYP2C19*2/*2, CYP3A5*3/*3 (nonexpresser) and ABCB1 (3435 TT, 1236 computed tomography, 2677 TT) genotype...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glomerulonephritis, Membranous

Share to Immunosuppressive Agents

Share to Omeprazole

Share to Polymorphism, Single Nucleotide

Share to Tacrolimus

Source

Identifiers

PMID: 35916550
DOI: 10.1097/FPC.0000000000000478

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigation of pharmacologic interactions between omeprazole and tacrolimus in a membranous nephropathy patient with CYP3A5 nonexpresser: a case report.PMID 35916550Read ↗

Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles.Semantic proximity Read ↗

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients.Semantic proximity Read ↗

A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

CYP3A5 Polymorphisms Leading to Tacrolimus Toxicity Following an Adult Renal Transplant.Semantic proximity Read ↗

In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.Semantic proximity Read ↗

Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics.Semantic proximity Read ↗

Investigation of the Impact of CYP3A5 and CYP2C19 Polymorphisms on Drug-Drug Interactions between Tacrolimus and Voriconazole Based on Physiologically-Based Pharmacokinetic ModelingSemantic proximity Read ↗

Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.Semantic proximity Read ↗

A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient.Semantic proximity Read ↗

Understanding and Preventing Adverse Effects of Tacrolimus Metabolization in Transplant Patients.Semantic proximity Read ↗

Predictors of tacrolimus dose optimization when drug-drug interaction associated with voriconazole in heart transplant recipientsSemantic proximity Read ↗

The effect of CYP3A5 genetic polymorphisms on adverse events in patients with ulcerative colitis treated with tacrolimus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.